HGH Fragment 176-191

Molecular Profile

Type

Synthetic peptide (cyclic, 16 residues)

Molecular formula

C78H123N23O22S2

Molecular weight

~1,817 g/mol

CAS number

66004-57-7

Amino acids

16

Sequence

FLRIVQCRSVEGSCGF

Modification

Unmodified C-terminal hGH fragment (no N-terminal tyrosine extension); intramolecular Cys7–Cys14 disulfide bond forming a cyclic (7→14) loop. This distinguishes it from AOD-9604, the Tyr-extended modified analog.

Mechanism & Target Class

A disulfide-cyclized 16-residue peptide corresponding to the C-terminal segment of a 191-residue parent protein, closed by a single intramolecular Cys7–Cys14 disulfide bond into a cyclic (7→14) loop. The published primary literature places the sequence at residues 177–191; "176-191" is the widespread secondary-literature nomenclature for the same fragment. NMR conformational analysis of the cyclic peptide identifies type I β-turns and describes how the Cys–Cys loop constrains the backbone. It is the native, unmodified parent of the later analog AOD-9604, which adds an N-terminal tyrosine extension; the present fragment carries no such extension.

Storage & Handling

Lyophilized

-20 °C or colder, protected from light and moisture; stable for extended periods when kept frozen and sealed.

Handling

Avoid repeated freeze–thaw cycles; protect from light and moisture; the Cys7–Cys14 disulfide is oxidation-sensitive — avoid reducing agents. As the unmodified fragment, it lacks the N-terminal tyrosine that the AOD-9604 analog uses to improve stability.

Primary Database

PubChem CID 16131230 ↗

References (24)

1. Reviews

   1

   Kopchick JJ, et al. (2020). Nat Rev Endocrinol

   DOI: 10.1038/s41574-019-0280-9PubMed 31780780

2. 2

   Vijayakumar A, et al. (2010). Growth Horm IGF Res

   DOI: 10.1016/j.ghir.2009.09.002PubMed 19800274

3. 3

   Mendias CL, Awan TM. (2026). Sports Medicine

   DOI: 10.1007/s40279-026-02437-0PubMed 41966639

4. 4

   Liao HJ, et al. (2024). Cartilage

   DOI: 10.1177/19476035241276406PubMed 39291443

5. 5

   Moré MI, Kenley D. (2014). Journal of Endocrinology and Metabolism

   DOI: 10.14740/jem213w

6. 6

   Stier H, Vos E, Kenley D. (2013). Journal of Endocrinology and Metabolism

   DOI: 10.4021/jem157w

7. Primary research

   7

   Wu Z, Ng FM. (1993). Biochem Mol Biol Int

   PubMed 8358331

8. 8

   Wijaya E, Ng FM. (1993). Biochem Mol Biol Int

   PubMed 8118430

9. 9

   Ng FM, et al. (2000). J Mol Endocrinol

   DOI: 10.1677/jme.0.0250287PubMed 11116208

10. 10

    Ng FM, et al. (2000). Horm Res

    DOI: 10.1159/000053183PubMed 11146367

11. 11

    Heffernan MA, et al. (2000). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.2000.279.3.E501PubMed 10950816

12. 12

    Ogru E, et al. (2000). J Pept Res

    DOI: 10.1034/j.1399-3011.2000.00771.xPubMed 11152298

13. 13

    Heffernan M, et al. (2001). Endocrinology

    DOI: 10.1210/endo.142.12.8522PubMed 11713213

14. 14

    Heffernan MA, et al. (2001). Int J Obes

    DOI: 10.1038/sj.ijo.0801740PubMed 11673763

15. 15

    Dietz J, Schwartz J. (1991). Metabolism

    DOI: 10.1016/0026-0495(91)90006-iPubMed 1861630

16. 16

    Sharma VM, et al. (2019). Am J Physiol Endocrinol Metab

    DOI: 10.1152/ajpendo.00129.2018PubMed 30325658

17. 17

    Høyer KL, et al. (2020). Physiol Rep

    DOI: 10.14814/phy2.14373PubMed 32073221

18. 18

    Zhao L, Jiang H. (2023). Front Endocrinol

    DOI: 10.3389/fendo.2022.1028191PubMed 36686475

19. 19

    Huang J, et al. (2023). Endocrinology

    DOI: 10.1210/endocr/bqad151PubMed 37897489

20. 20

    Cox HD, et al. (2015). Drug Test Anal

    DOI: 10.1002/dta.1715PubMed 25208511

21. 21

    Vanhee C, et al. (2014). Drug Test Anal

    DOI: 10.1002/dta.1687PubMed 24976118

22. 22

    Orlovius AK, et al. (2013). Drug Test Anal

    DOI: 10.1002/dta.1557PubMed 24124033

23. 23

    Kwon DR, Park GY. (2015). Ann Clin Lab Sci

    PubMed 26275694

24. 24

    Ng FM, Bornstein J. (1978). American Journal of Physiology

    DOI: 10.1152/ajpendo.1978.234.5.E521PubMed 645904